Boehringer Launches Switched Flomax Relief MR For BPH In U.K.
This article was originally published in The Tan Sheet
Executive Summary
Boehringer Ingelheim's U.K. launch of nonprescription Flomax Relief MR for benign prostatic hyperplasia opens a new switch category abroad, but a similar Rx-to-OTC move in the U.S would be more difficult, one expert says